Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00443820
First received: March 2, 2007
Last updated: March 22, 2011
Last verified: March 2011
  Purpose

This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.


Condition Intervention Phase
Onychomycosis
Drug: terbinafine
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.


Secondary Outcome Measures:
  • Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.

  • Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

    Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and <= 10% residual involvement of the target toenail.

    Clinical effectiveness was a composite binary variable defined as "Yes" if:

    • If mycological cure (negative KOH and negative culture for dermatophytes) and
    • = 10% residual involvement of the target toenail "No" if otherwise

  • Safety and Tolerability Assessed by the Number of Participants With Adverse Events [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]
    Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.


Enrollment: 526
Study Start Date: December 2006
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
Drug: terbinafine
Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
Other Name: Lamisil
Placebo Comparator: 2
Vehicle (placebo) for 48 weeks
Drug: Placebo
Vehicle (placebo) once daily for 48 weeks
Experimental: 3
Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
Drug: terbinafine
Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
Other Name: Lamisil
Placebo Comparator: 4
Vehicle (placebo) for 24 weeks
Drug: Placebo
Vehicle (placebo) once daily for 24 weeks

  Eligibility

Ages Eligible for Study:   12 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and females 12 - 75 years of age
  • Fungal toenail infection of one or both of the large (great) toenails
  • The nail infection must be due to a dermatophyte, (mixed infections dermatophyte and non-dermatophyte] are not allowed)

Exclusion Criteria:

  • Target foot must not have severe plantar (moccasin) tinea pedis that would require systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be treated with terbinafine prior to baseline or at any time during the trial. Other topical treatments for athlete's foot may be recommended at the discretion of the investigator.
  • Subjects must not have abnormalities of the nail that could prevent a normal appearing nail if clearing of infection is achieved
  • No administration of systemic antifungal medications within 6 months prior to screening visit
  • No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
  • No professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
  • Known pregnancy or lactation at time of enrollment

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00443820

  Hide Study Locations
Locations
United States, California
Dr. Fred D. Youngswick
Novato, California, United States, 94945
United States, Colorado
Dr. Larry Doehring
Northglenn, Colorado, United States, 80234
United States, Florida
Dr. Robert P. Dunne
Melbourne, Florida, United States, 32935
United States, Georgia
Dr. Mark Ling
Newnan, Georgia, United States, 30263
United States, Illinois
Dr. Jesse Plasencia
Chicago, Illinois, United States, 60632
United States, Kansas
Dr. John Mallory
Overland Park, Kansas, United States, 66215
Dr. Jeffrey Conrow
Topeka, Kansas, United States, 66606
United States, Louisiana
Dr.Michael Kaye
Covington, Louisiana, United States, 70433
United States, Maryland
Dr. Max Weisfeld
Baltimore, Maryland, United States, 21214
United States, Michigan
Dr. Linda Stein-Gold
Detroit, Michigan, United States, 48202
United States, Missouri
Dr. Anna Glaser
St. Louis, Missouri, United States, 63104
United States, New York
Dr. Richard Scher
New York, New York, United States, 10032
United States, North Carolina
Dr. Joseph Jorrizo
Winston Salem, North Carolina, United States, 27157
United States, Ohio
Dr. Anne Lucky
Cincinnati, Ohio, United States, 45230
United States, Oregon
Dr. Rich Phoebe
Portland, Oregon, United States, 97210
United States, South Carolina
Dr. Patricia Westmorland
Simpsonville, South Carolina, United States, 29681
United States, Tennessee
Dr. David Horowitz
Nashville, Tennessee, United States, 37203
United States, Texas
Dr. Jay Lifshen
Irving,, Texas, United States, 75061
Dr. Richard Pollak
San Antonio, Texas, United States, 78229
United States, Virginia
Dr. Patrick Agnew
Virginia Beach, Virginia, United States, 23464
France
Novartis Investigative Site
Various Cities, France
Germany
Novartis
Investigative Site, Germany
Novartis Investigative Site
Various cities, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00443820     History of Changes
Other Study ID Numbers: CSFO327N2302
Study First Received: March 2, 2007
Results First Received: January 19, 2011
Last Updated: March 22, 2011
Health Authority: United States: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Novartis:
Toenail fungus
Onychomycosis
Nail fungus
Toenail fungal infection
Tinea unguium
Dermatophytes
Foot dermatoses

Additional relevant MeSH terms:
Onychomycosis
Tinea
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Nail Diseases
Skin Diseases
Terbinafine
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 24, 2014